Cessatech aktie (CESSA) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Morgonkollen: Aktuella händelser du bör ha koll på

Pressmeddelanden från Cessatech

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Cessatech updates the milestones for the coming year

· Great progress from the year 2024, including the commercialization agreement for CT001.

Cision • 23 Dec 2024 12:00

Third Quarter Report Q3-2024

The Company has advanced well with its planned activities · Commercial partnership agreement with Proveca Ltd · Good progress with Paed...

Cision • 13 Nov 2024 13:00

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

· 75 paediatric patients have now been recruited in Study 0202 · Study 0202 is the final required clinical study that will evaluate the...

Cision • 16 Oct 2024 10:00

Cessatech and Proveca partnership - Q&A

Selected top 10 investor questions

Cision • 02 Sep 2024 10:00

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.

Cision • 26 Aug 2024 08:30

Second Quarter Report Q2-2024

The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pa...

Cision • 21 Aug 2024 08:30

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001

· The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 m...

Cision • 12 Aug 2024 11:50

Key Cessatech priorities for the rest of the year

· The US launch is almost there · More paediatric data to be presented at IASP 2024, World Congress on Pain · Commercial partnerships...

Cision • 02 Aug 2024 15:00

Grant of incentive warrants to Employees, CEO and the Board of Directors

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant a new incentive warrants to existing and new emp...

Cision • 26 Jul 2024 16:00

Cessatech announces changes to the Board of Directors

Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the Company’s extraordinary general meeting.

Cision • 05 Jul 2024 14:36

Minutes of the Extraordinary General Meeting – 5 July 2024

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its extraordinary general meeting on Friday 5 July 2024 at 08:30 (CET) a...

Cision • 05 Jul 2024 14:31

Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

· Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young ...

Cision • 28 Jun 2024 12:10

EXTRAORDINARY GENERAL MEETING

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the extraordinary general meeting to be held on Friday, 5 July 2024.

Cision • 20 Jun 2024 16:00

Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.

· The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and plac...

Cision • 03 Jun 2024 13:00

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

· First patient has been dosed in Safety Study 0202 of lead candidate CT001.

Cision • 27 May 2024 14:53

First Quarter Report Q1-2024

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2024.

Cision • 15 May 2024 08:45

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Wednesday 27 March 2023 at 09:00 (CET) at ...

Cision • 27 Mar 2024 11:00

Annual General Meeting - 27 March 2024

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 27 March 2024.

Cision • 11 Mar 2024 17:00

Cessatech A/S publishes Annual Report for the fiscal year 2023

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2023, which also includes the fourth qua...

Cision • 29 Feb 2024 09:00

CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2

Copenhagen, Denmark, January 30, 2024 - Today, Cessatech A/S ("Cessatech” or the "Company") announces the outcome of the exercise of warrant...

Cision • 30 Jan 2024 08:30

Correction: LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024

In the press release published earlier today the MAR label was placed by mistake.

Cision • 23 Jan 2024 17:41

LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024

Copenhagen, Denmark, January 23, 2024 - Tomorrow, January 24, 2024, is the last day of trading in warrants of series TO2 (the "Warrants").

Cision • 23 Jan 2024 17:02

CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2

Copenhagen, Denmark, January 22, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that all members of the Company’s Senior Mana...

Cision • 22 Jan 2024 08:30

CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2

Copenhagen, Denmark, January 12, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that today begins the exercise period for the...

Cision • 12 Jan 2024 08:00

CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD

Copenhagen, Denmark, January 11, 2024 – Cessatech A/S (“Cessatech” or the "Company") announces that the exercise price for the warrants of s...

Cision • 11 Jan 2024 08:00

Q&A session related topline data Study 0205

On 4 January – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive fee...

Cision • 04 Jan 2024 17:30

Third Quarter Report Q3-2023

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2023.

Cision • 16 Nov 2023 08:30

Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children

· The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number of children required in the final safety study (02...

Cision • 25 Oct 2023 08:00

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

· Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comp...

Cision • 21 Sep 2023 13:55

Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children

· The Paediatric Committee (PDCO) under The European Medicines Agency (EMA) has agreed to the Paediatric Investigational Plan (PIP) for C...

Cision • 12 Sep 2023 08:45

Second quarter report Q2-2023

· US co-development and commercialization partnership signed for CT001 - potential income already from 2024 · Strong clinical progress ...

Cision • 24 Aug 2023 17:30

Cessatech secures DKK 5 million loan facility agreement to support the US launch of its lead program CT001

· Loan facility agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S, which includes some existing share...

Cision • 17 Aug 2023 17:30

Cessatech - Ventis Pharma US partnership - Q&A

On 30 June – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive feedb...

Cision • 30 Jun 2023 08:58

Cessatech and Ventis Pharma announce US partnership for CT001

· Cessatech and Ventis Pharma enter a co-development and commercialization royalty license agreement for CT001 sharing net profits · CT...

Cision • 27 Jun 2023 07:50

Cessatech provides positive news regarding shelf life of CT001

· The ongoing stability studies of CT001 have provided confidence in achieving a shelf life of more than two years at controlled room tem...

Cision • 31 May 2023 08:30

First quarter report Q1-2023

· Study 0205 is progressing, with last patient expected in Q3 · Protocol finalized for study 0202, ready for submission in Q2 · Good ...

Cision • 12 May 2023 08:00

April business update - the business strategy

We are well into 2023 and are progressing with our plans.

Cision • 19 Apr 2023 10:43

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Thursday 23 March 2023 at 09:00 (CET) at t...

Cision • 23 Mar 2023 14:00

Cessatech announces new Chairman of the Board

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has appointed Martin Olin as new Chairman of the Board

Cision • 23 Mar 2023 14:00

Annual General Meeting - 23 March 2023

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 23 March 2023.

Cision • 08 Mar 2023 17:00

Cessatech A/S publishes Annual Report for the fiscal year 2022

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2022, which also includes the fourth qua...

Cision • 28 Feb 2023 16:30

Welcome to 2023 and our January business update...

We welcome the year 2023 which is a very exiting year for Cessatech, we are expecting many milestone and we want to give you and update on o...

Cision • 27 Jan 2023 07:30

Grant of incentive warrants to Employees, CEO and the Board of Directors

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant new incentive warrants to existing and new emplo...

Cision • 17 Jan 2023 17:30

CESSATECH’S COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE HAS BEEN REGISTERED

Copenhagen, Denmark, December 7, 2022 – On November 24, 2022, Cessatech A/S (“Cessatech” or the “Company”) announced the resolution of the b...

Cision • 07 Dec 2022 16:00

CESSATECH’S BOARD RESOLVES ON COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE

København, Denmark, November 24, 2022 – At a board meeting today the board of directors in Cessatech A/S (“Cessatech” or the “Company”) reso...

Cision • 24 Nov 2022 17:00

CESSATECH ANNOUNCES LAST DAY OF TRADING IN BTU AND THE FIRST DAY OF TRADING IN WARRANTS OF SERIES TO2

København, Denmark, November 18, 2022 – The rights issue announced on October 19, 2022 in Cessatech A/S has been registered with the Danish ...

Cision • 18 Nov 2022 16:45

Third quarter report Q3-2022

· Successful outcome of trial 0206, a phase 2 pharmacokinetics trial in children undergoing elective surgical procedures · First patien...

Cision • 18 Nov 2022 08:30

CESSATECH ANNOUNCES OUTCOME OF RIGHTS ISSUE

København, Denmark, November 14, 2022 – The results of the rights issue announced on October 19, 2022 for which the subscription period ende...

Cision • 14 Nov 2022 14:06

TOMORROW IS THE LAST DAY OF THE SUBSCRIPTION PERIOD IN CESSATECH’S RIGHTS ISSUE

København, Denmark, November 8, 2022 – Cessatech A/S (“Cessatech” or the “Company”) announces that the subscription period for the Company’s...

Cision • 08 Nov 2022 11:18

Minutes of the Extraordinary general meeting

Cessatech A/S, CVR no. 41 29 30 55 (“Cessatech” or the “Company”) held an extraordinary general meeting on Friday 4 November 2022, at 8:00 (...

Cision • 04 Nov 2022 10:21

THE SUBSCRIPTION PERIOD HAS STARTED IN CESSATECH’S RIGHTS ISSUE

København, Denmark, October 27, 2022 – Cessatech A/S (“Cessatech” or the “Company”) announces that the subscription period for the Company’s...

Cision • 27 Oct 2022 17:30

Extraordinary general meeting

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the extraordinary general meeting to be held on Friday 4 November 2022.

Cision • 20 Oct 2022 18:00

Correction MAR-label: CESSATECH PUBLISHES OFFERING MEMORANDUM IN CONNECTION WITH 80% GUARANTEED RIGHTS ISSUE

København, Denmark, October 20, 2022 – Cessatech A/S (“Cessatech” or the “Company”) today released the Offering Memorandum in connection wit...

Cision • 20 Oct 2022 08:30

CESSATECH ANNOUNCES DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL DEVELOPMENT OF CT001

København, Denmark, October 19, 2022 – The Board of Directors of Cessatech A/S (“Cessatech” or the “Company”) has today resolved to carry ou...

Cision • 19 Oct 2022 18:00

Great progress during Q3 – more to come

Great progress during Q3 – more to come

Cision • 10 Oct 2022 17:00

Cessatech reports successful outcome of pharmacokinetic trial in children of lead candidate

· Clinical trial 0206 investigated the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.

Cision • 23 Sep 2022 08:30

Cessatech reports first patient dosed in pivotal trial of lead product candidate

· First patient has been dosed in pivotal trial of lead candidate CT001 · The pivotal trial, trial 0205, will investigate the postopera...

Cision • 05 Sep 2022 17:30

Second quarter report Q2-2022 – green light for the pivotal trial 0205

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2022.

Cision • 19 Aug 2022 08:30

Good things are worth waiting for - welcome to the second half of 2022!

We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that w...

Cision • 11 Aug 2022 08:30

Cessatech reports Regulatory Green Light for trial 0205, the pivotal trial for CT001 - first patient expected shortly

· Trial 0205, the pivotal trial, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted...

Cision • 30 Jun 2022 17:00

Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate

· Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.

Cision • 16 May 2022 08:15

First quarter report Q1-2022 - preparing for the pivotal trial

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2022.

Cision • 19 Apr 2022 17:30

Newsletter #6 - Mar 2022

Newsletter #6 - Mar 2022

Cision • 31 Mar 2022 09:00

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Thursday 17 March 2022 at 08:00 (CET) as a...

Cision • 17 Mar 2022 16:30

Cessatech reports successful outcome of bioavailability trial 0204 with CT001

Topline results of clinical trial 0204 investigating the absolute bioavailability of CT001 showed clinical relevant exposures following nasa...

Cision • 08 Mar 2022 08:30

Cessatech A/S publishes annual report for the fiscal year 2021

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2021.

Cision • 03 Mar 2022 08:45

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 17 March 2022.

The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Thursday 17 ...

Cision • 02 Mar 2022 09:00

Fourth quarter report Q4-2021 - preparing for the pivotal trial

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 October – 31 December 2021.

Cision • 24 Feb 2022 08:00

Cessatech expects to report on its bioavailability trial 0204 within a few weeks

Topline results of clinical trial 0204 in healthy volunteers investigating the absolute bioavailability of CT001, which was set to be announ...

Cision • 22 Feb 2022 08:58

Cessatech announces changes to the Board of Directors

Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with the intention that she will be proposed as a membe...

Cision • 06 Jan 2022 08:00

Cessatech’s warrant exercise registered with the Danish Companies Registration Office

Copenhagen, Denmark, 4 January 2022 – On Thursday, 16 December 2021, the exercise period for Cessatech A/S ("Cessatech" or the “Company") wa...

Cision • 04 Jan 2022 17:00

Newsletter update #5 - Dec 2021

Newsletter update #5 - Dec 2021

Cision • 30 Dec 2021 16:00

Cessatech successfully raises approx. DKK 24.3 million through warrant exercise and does not activate guarantee commitments

During the period 25 November – 16 December 2021, holders of TO 1 have been entitled to subscribe for shares with warrants.

Cision • 22 Dec 2021 13:07

Last day of trading in Cessatech’s warrants of series TO 1 is today Tuesday 14 December 2021

Copenhagen, Denmark, 14 December 2021 – Tuesday, 14 December 2021, is the last day of trading in warrants of series TO 1 on Spotlight Stock ...

Cision • 14 Dec 2021 08:00

CEO and Board of Directors have exercised warrants of series TO 1

Copenhagen, Denmark, 8 December 2021 – The CEO and members of the Board of Directors of Cessatech A/S (“Cessatech” or the “Company”) have ex...

Cision • 08 Dec 2021 08:00

The exercise period for warrants of series TO 1 begins today

Copenhagen, Denmark, 25 November 2021 – Today, 25 November 2021, marks the beginning of the exercise period for the warrants of series TO 1 ...

Cision • 25 Nov 2021 08:07

Third quarter report Q3-2021 - focusing on next trial (0205)

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2021.

Cision • 19 Nov 2021 08:00

Newsletter #4 - Nov 2021, Preparing for next year...

Preparing for next year... We continue to make good progress with the clinical activities for CT001, and 2022 will be a very interesting yea...

Cision • 12 Nov 2021 17:30

Cessatech annonces the issuance of its first US patent covering CT001

Copenhagen, Denmark, 02 November 2021 – Cessatech A/S (“Cessatech” or the “Company”) announces that the United States Patent and Trademark O...

Cision • 02 Nov 2021 18:00

Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate

Clinical trial 0206 will investigate the pharmacokinetics  in children aged 1-17 undergoing elective surgical procedures.

Cision • 20 Aug 2021 08:00

Second quarter report Q2-2021 - planning for the pivotal trials

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2021.

Cision • 19 Aug 2021 08:00

Newsletter: Preparing for the pivotal studies....

We continue to make firm progress with the clinical activities for CT001.

Cision • 30 Jun 2021 19:00

Cessatech announces new Chairman of the Board - getting ready for the pivotal studies

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has appointed Adam Steensberg as new Chairman of the Board.

Cision • 29 Jun 2021 08:07

Cessatech reports last subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports last subject dosed ahead of timeli...

Cision • 31 May 2021 07:45

Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide's reviewers found an average of 2.

Cision • 14 May 2021 07:45

First quarter report Q1-2021 - ‘one down, two to go’ of the major milestones of 2021

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2021.

Cision • 19 Apr 2021 08:00

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Friday 26 March 2021 at 08:00 (CET) at Kan...

Cision • 26 Mar 2021 18:28

Cessatech reports first subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001.

Cision • 24 Mar 2021 08:30

Cessatech A/S publishes annual report for the fiscal year 2020

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2020.

Cision • 11 Mar 2021 17:43

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 26 March 2021.

The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Friday 26 Ma...

Cision • 10 Mar 2021 08:00

Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial

CFI.co - a journal and online resource reporting on business, economics and finance - announced that Cessatech A/S (“Cessatech”) won the 202...

Cision • 09 Mar 2021 08:00

Favourable data from the Registry Safety Study

First major milestone reached: Data from the Registry Safety Study (0203) Cessatech A/S announces positive, top line data from a retrospecti...

Cision • 04 Mar 2021 08:30